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ABSTRACT: Famotidine (FMT), a histamine H2-receptor antagonist, is a drug commonly used in treatments of gastroesophageal diseases
that presents solid-state polymorphism (A and B forms), the marketed form being the metastable polymorph B. A new stable salt was
obtained by combination of FMT and maleic acid as coformer. FMT maleate (FMT-MLT) was prepared either by solvent evaporation or
comilling methods. Single-crystal X-ray diffraction reveals that (FMT)+ in FMT-MLT adopts an extended conformation that is stabilized by
classical and nonclassical H-bonds. The three-dimensional packing consists of tapes along the axis b that further develop a columnar array
based on H-bonds involving (FMT)+ side chain. Nonconventional –stacking interactions between adjacent tapes were also identified.
Fourier transform infrared, differential scanning calorimetry, thermogravimetric analysis, polarized light thermal microscopy, and scanning
electronmicroscopywere employed to characterize themulticomponent complex. According to the solubility values in water and simulated
gastric fluid, FMT-MLT exhibits such a performance that improves on the solubility of the commercially available polymorph. Finally, the
higher stability of FMT-MLT regarding both FMT forms, as well as its easy preparation from either A or B forms or a mixture of them, also
allows to consider this salt as a valuable alternative to avoid the polymorphism issue in marketed formulations containing FMT. C© 2014
Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3754–3763, 2014
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INTRODUCTION
In recent years, the crystal engineering of pharmaceutical
solids has achieved considerable development in the phar-
maceutical industry.1–3 The design of new multicomponent
solid-state assemblies, with improved properties, based on
supramolecular synthons is the main goal in this area. The
most commonmulticomponent systems of APIs (active pharma-
ceutical ingredients) are salts, which involves proton transfer
from the acidic to the basic moiety, thus forming ionic compo-
nents with opposite charges. On the contrary, cocrystals are
obtained when proton transfer does not occur. The formation
of a salt or a cocrystal depends upon the pKa of the API and
the coformer molecule. Several studies were carried out in or-
der to evaluate the extent of proton transfer in the solid-state
aiming to establish whether a salt, a cocrystal or a compound
with mixed ionization states is obtained. Childs et al.4 propose
a guideline known as “rule of three” that states that salts are
expected if the pKa [pKa(base) − pKa(acid)] is greater than 2
or 3 units, whereas cocrystals will be obtained when pKa is
negative. These pKa values were recently revised using crys-
tallographic data from the Cambridge Structural Database and
calculated pKas in Marvin for over 6000 acid base adducts.5 As
a result, it is accepted that cocrystals or salts will be obtained if
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pKa < −1 or >4, respectively, whereas in the pKa range −1
to 4, salts, cocrystals, or compound containing mixed ionization
states could be obtained.
It is well known that more than one-third of drug in phar-
maceutical industry show polymorphism.6,7 Thus, even though
the most stable solid form would be the recommendable one
for solid dosage formulations to prevent phase transformations
during the processing or storage, several cases of phase tran-
sitions have been reported when the therapeutically preferred
but metastable form is used.8–11 Then, regulatory authorities
encourage the pharmaceutical companies to investigate and
control drug polymorphism to ensure product quality, safety,
and performance.12 Incorrect formulations containingmixtures
of polymorphs also constitute another issue to solve. Such is
the case of mebendazole, where not only the pharmacologically
preferred form (C) but also the inactive one (A) were found
in several marketed products.13,14 Two mebendazole salts with
improved solubility were synthesized from either A, B, or C
polymorphs.15,16 Thus, a simple reaction constitutes a valuable
alternative to obtain a compound with appropriate properties
able to avoid the polymorphism problem in pharmaceutical
formulations. Famotidine (FMT), an orally active histamine
H2-receptor antagonist, is a classic example of conformational
polymorphism.17 Two polymorphic forms have been previously
reported, that is, the A form (A-FMT) that exhibits an extended
conformation, and the B form (B-FMT) that adopts a folded
one.18 The B polymorph is preferred for commercial formula-
tions because of its physical properties that confer it higher
bioavailability.19 However, it is a metastable form and there-
fore stability problems related to conversion to the more stable
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A form can be expected during processing and storage. It is note-
worthy that polymorphic transformation fromB- to A-FMTwas
achieved by the manual grinding method.20 In addition, FMT
belongs to class IV (low solubility and low permeability) ac-
cording to the Biopharmaceutical System Classification21 and
therefore its bioavailability is seriously limited. Several strate-
gies have been developed to increase its solubility, such as
preparation of solid dispersions,22,23 conversion to the amor-
phous state,24 synthesis of inclusion complexes,25–27 and re-
duction of particle size.28 However, the introduction of mod-
ifications at the molecular level of FMT by incorporating
coformers into a unique crystal latticemaintaining the covalent
bonding of the API still remains an almost unexplored field.
A strategy for the prediction and selection of drug substance
salt forms was developed by Brittain.29 Its utility was further
demonstrated on FMT by predicting the existence of a num-
ber of salts and synthesizing one of them with salicylic acid as
salt-forming agent. FMT salicylate exhibits much larger solu-
bility than that of FMT and was characterized by powder X-ray
diffraction (PXRD), IR spectroscopy, and differential scanning
calorimetry (DSC) measurements.30
In thiswork, crystal engineering conceptswere taken into ac-
count to obtain a compound with improved properties in which
the solid-state phase transition of the metastable B-FMT to the
more stable A-FMT form could be avoided. To this end, maleic
acid—a dicarboxylic acid that is pharmaceutically acceptable
and appears on the GRAS (generally recognized as safe)31 list—
was selected as coformer as the carboxylic groups are potential
candidates to participate in supramolecular heterosynthons
with FMT. Thus, single crystals of FMT maleate (FMT-MLT)
were obtained from recrystallization of FMT in a maleic acid
methanolic solution. Additionally, FMT-MLT microcrystalline
powder was also obtained by the comilling process, broadly ac-
cepted in the pharmaceutical industry. The milling time was
standardized by the relative degree of crystallinity (RDC%)
analysis. FMT-MLT was fully characterized and the results
were compared with those corresponding to A and B polymor-
phic forms of FMT. To this aim, solid-state techniques such as
Fourier transform infrared (FTIR), PXRD, DSC, thermogravi-
metric analysis (TGA), Polarized light thermal microscopy, and
scanning electron microscopy (SEM) were employed. Finally,
the solubility values in water and simulated gastric fluid (SGF)
were determined employing the shake-flask procedure.
EXPERIMENTAL
Material
Famotidine (MW: 337.4 g/mol) was purchased as a polymor-
phic mixture of A and B forms from Fluka Analytical R© (Sigma-
Aldrich Co, St.Louis, Missouri) and used as received for all
synthesis processes. The pure A and B polymorphs were ob-
tained as described in Hassan et al.32 and tested by comparing
the corresponding powder X-ray diagrams and IR spectra with
those reported in the literature.19
Synthesis of FMT-MLT
Solvent Evaporation Method
A solution containing 109 mg (0.3 mmol) of FMT (A–B forms
mixture) in 50 mL of boiling anhydrous methanol was added
to the same volume of a methanolic maleic acid solution
(40.22 mg, 0.3 mmol) and vigorously stirred for 60 min. The
resulting solution was kept for 2 days at 25◦C yielding colorless
needle-shaped crystals, suitable for the crystallographic char-
acterization. The synthesis from the pure A or B forms led to
identical results. In addition, FMT-MLT was also obtained as
polycrystalline powder from other solvents as boiling water and
absolute ethanol. The obtained products were filtered, washed
with hexane–methanol (10:1), and dried under room conditions
for further characterization.
Comilling Method
Famotidine (436 mg, 1.2 mmol) and maleic acid (278.4 mg, 1.2
mmol) were comilled using an oscillatory ball mill Mixer Mill
MM400RETSCH (RetschGmbH,Haan, Germany). The sample
powder was placed in a 25-mL volume stainless steel milling jar
containing two 7-mm diameter stainless steel balls and milled
at a frequency of 25 Hz. Milling was conducted in a room at
25 ± 2◦C for 180 min; the jar was immersed into liquid nitro-
gen each 40 min. The crystallinity of the samples at different
milling times was evaluated by PXRD using the RDC analy-
sis. RDC could be defined as the ISA–IREF ratio, where ISA is
the diffraction peak height of the sample under study, whereas
IREF is the peak height at the same angle (22) of a reference.
The intensity of the peak at 20.54 22angle in the experimental
diffractogram of FMT-MLT obtained by the solvent evaporation
method was taken as IREF in the present case.
Methods
Single-crystal X-ray diffraction measurements were carried
out at 100(2) K on a Bruker APEX II-DUO Diffractome-
ter (Bruker Corporation, MA) equipped with Bruker Kryoflex
open flow cryostat enabling low-temperature data collection
using CuK" radiation (1.5418 A˚). Unit cell determination,
data collection, and integration were obtained with APEX II
and SAINT software (Bruker Corporation, MA).33,34 Multiscan
absorption corrections were applied using SADABS program
based on Blessing’s method.35,36 The structure was solved by
direct methods with SHELXS-97 and all nonhydrogen atoms
were anisotropically refined by full-matrix least-squares tech-
niques on F2 using SHELXL-97.37,38 The C–H hydrogen atoms
were stereochemically positioned and refined with fixed indi-
vidual displacement parameters [Uiso(H) = 1.2 Ueq(Csp2) or
1.5 Ueq(Csp3)] using a riding model with aromatic C–H bond
length of 0.93 A˚ and methylene C–H one of 0.97 A˚. The N–H,
N+–H, and O–H hydrogen atoms were found in the differ-
ence Fourier map and their positions freely refined with fixed
isotropic thermal parameters [Uiso(H) = 1.2 Ueq(N) or 1.5
Ueq(O)].
Positional disorder in C(10) and C(11) atoms was satisfac-
torily solved. Different populations of disordered conformers
labeled as A (60%) and B (40%) occur in two opposite orien-
tations across the screw axis. Considering that the crystal is
a twin, the twin orientation matrix and the refined twin ratio
(defined as the fractional contribution of each twin component)
that allow the structural solution were found to be (1 0 1 0 -1 0
0 0 -1) and 0.4, respectively. Crystalline habit of the FMT-MLT
exhibiting its twin nature is shown in Figure S1. The analy-
sis of the intramolecular geometric parameters of (FMT)+ in
FMT-MLT was performed with MOGUL39 applying the follow-
ing filters:R factor less than 5% and exclusion of metal–organic
compounds. SHELXL-97,37,38 ORTEP-3,40 and MERCURY41
DOI 10.1002/jps.24196 Russo et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:3754–3763, 2014
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programs were used within WinGX42 to prepare materials for
publication. The crystallographic information file (CIF) loading
the data sets (excluding the structure factors) for FMT-MLT
has been deposited in the Cambridge Structural Data Base un-
der deposit code CCDC 1012192 (copies of these data may be
obtained free of charge from The Director, CCDC, 12 Union
Road, Cambridge CB2 1EZ, UK, fax: 44–123–336–033; e-mail:
deposit@ccdc.cam.ac.uk or http://www.ccdc.cam.ac.uk).
Fourier transform infrared spectra were recorded on a Nico-
let PROTE´GE´ 460 Spectrometer (Nicolet Instrument Corpora-
tion, Madison, Wisconsin) provided with a CsI beamsplitter in
the 4000–400 cm−1 range with 64 scans and spectral resolution
of 2 cm−1 using the KBr pellet technique.
X-ray powder diffraction diagrams were obtained with a
Rigaku ULTIMA IV diffractometer (Rigaku Co, Tokio, Japan)
using CuK" radiation (Ni-filter) and NaCl and quartz as exter-
nal calibration standards. The diffractograms were recorded in
the 22angle range 3◦–45◦ and the process parameters were set
at 0.02 22 scan step size and 2 s scan step time.
Differential scanning calorimetry curves were obtained with
a Shimadzu TA-60WS Thermal Analysis System (Shimadzu
Inc., Kyoto, Japan) using 3–5 mg of each sample in open alu-
minum pans with flowing air at 50 mL/min and a heating rate
of 10◦C/min from room temperature (RT) to 200◦C. Calibration
of the DSC instrument was carried out using indium as stan-
dard. The Tg (glass transition temperature) was determined
as the midpoint of the change in heat capacity of the samples,
whereas both Tc (crystallization temperature) and Tm (melting
temperature) were determined as the onset temperatures. The
DSC analysis allows the monitoring of the solid-state modifica-
tions as a function of the milling time of the comilled samples.
Each assay was performed in triplicate.
Thermogravimetric analysis was performed using a Shi-
madzu TGA-51 Thermal Analyzer (Shimadzu Inc., Kyoto,
Japan) using platinum pans, flowing air at 50 mL/min and a
heating rate of 10◦C/min from RT to 800◦C.
Polarized light thermal microscopy experiments were per-
formed in a Linkam Hot-Stage system, model THMS600
equipped with a Leica DM2500 microscope and a Pixelink PL-
A662 video camera (Linkam Scientific Instruments Ltd. Mer-
stham,UnitedKingdom). LINKSYS 32DV-NC system software
by Linkam was used for temperature control and image record
and analysis. Images were obtained by the combined use of
polarized light and wave compensators using a 10× magnifica-
tion.
Scanning electron microscopy technique was used to ob-
serve and analyze the morphology of the samples that were
mounted on double-sided carbon adhesive tapes on alu-
minum stubs and gold coated (30 nm thickness) and pro-
cessed in a standard sputter prior to observation in a
LEO1450VP (LEO Electron Microscopy Ltd., Clifton Road,
England).
Solubility Assays
Equilibrium solubility studies were performed for FMT-MLT
and compared with A and B forms of FMT. Assays were car-
ried out in distilled water and SGF free of enzymes. The SGF
medium consists of a HCl/KCl (0.05 mol/L) acid buffer solution
at pH 2. An excess of the drugs was added into Eppendorf R©
tubes with 1.5 mL of dissolution medium. These aqueous sus-
pensions were shaken in a JEIO TECH SI-300R Shaker (JEIO
TECH Co. Ltd. Seoul, Korea) at 100 rpm at 37◦C during 24
and 1 h for water and SGF, respectively (see section Solubil-
ity Assays in Results). The resulting suspensions were filtered
with a 0.22-:m MilliporeR© (MERCK KGaA, Darmstadt, Ger-
many) membrane filters. The FMT concentration in the filtrate
was determined at 276 nm using a Shimadzu UV-160 A spec-
trophotometer (Shimadzu Inc., Kyoto, Japan) with CPS-240A
cell positioned using quartz cells (light-path = 10 mm); the
temperature was maintained at 25.0 ± 1◦C during the mea-
surements. Appropriate dilutions had to be prepared to fit the
linear range of 0.0105–0.0642 mg/mL. The solubility of each
sample was determined by triplicate. The calibration curve is
shown in Figure S2.
RESULTS
Crystal Structure Description
The experimental PXRD diagram fits well with the theoretical
one obtained by simulation with MERCURY41 inputting the
FMT-MLT CIF created after the structure refinement (Fig. S3).
Table 1 lists the data collection and refinement details from
the single-crystal X-ray diffraction experiment. Figure 1 shows
an ORTEP-340 view of the asymmetric unit of FMT-MLT that
contains one (FMT)+ and one (MLT)− ions. The intramolecular
hydrogen bonds in the asymmetric unit with their respective
distances and angles are listed in Table 2.
The intra- and intermolecular H-bonds involving the sul-
famoyl group (–SO2N2) in FMT-MLT are responsible for the dis-
torted tetrahedral geometry observed around the sulfur atom.
The geometrical parameters of –SO2N2 are listed in Table S1.
The structural analysis of the methylthiopropyl side chain of
(FMT)+ in FMT-MLT shows an extended conformation, similar
to that found in A-FMT. The dihedral angles of (FMT)+ in FMT-
MLT and A-FMT are summarized in Table 3. As can be seen,
the dihedral angles are comparable in both compounds except
for T4 that is significantly higher for the salt revealing that
the methylthiopropyl chain of (FMT)+ adopts a more extended
conformation (see Fig. S4).
The guanidine moiety in FMT contains three nitrogen atoms
susceptible of being protonated. The n–B possible conjugations
between the amino and imino N atoms increase the basicity
of the N-imine atom and decrease the basicity of the N-amine
ones.43 This is in agreement with the protonation of the N(3)
atom observed in the FMT-MLT difference Fourier map, as ex-
pected from the corresponding pKa (5.14) and the calculated
high degree of efficiency for salt formation,30 resulting in the
highly stable guanidinium group. The higher stability of this
group arises from both the Y-aromaticity and the favorable
positive charge distribution.43 The CN bond lengths and the
angular values are not equal as it would be expected for a free
guanidinium group; in fact, they are significantly different as a
consequence of not only the substitution (i.e., thiazole ring), but
also the presence of intra- and intermolecular H-bonds. An in-
tramolecular H-bond is observed between N(2) and N(4) atoms
(see Table 2), thus forming a six-membered ring. This inter-
action is stabilized by the resonance-assisted hydrogen bond
(RAHB) effect involving the H(2A)–N(2)–C(5)–N(3)–C(6)–N(4)
atoms.44,45 Moreover, it is the responsible of the coplanarity ob-
served between the thiazole ring and the guanidinium group
(see Fig. S5).
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Table 1. Crystal Data and Structure Refinement for FMT-MLT
Empirical Formula C12H19N7O6S3
Temperature 100.0(2) K
Formula weight 453.55
Wavelength (A˚) 1.54178
Crystal system Monoclinic
Space group P21/c
Unit cell dimensions (A˚, ◦) a = 17.6489(13) $ = 101.581(7)
b = 15.3720(10)
c = 7.0841(7)
Volume (A˚3) 1882.8(3)
Z 4
Density (calculated) (mg m−3) 1.600
Absorption coefficient (mm−1) 4.044
F(000) 944
Crystal size (mm) 0.24 × 0.04 × 0.04
2 range 5.76–67.2
Index ranges −21 ≤ h ≤ 20, −17 ≤ k ≤ 18, −8 ≤ l ≤ 7
Collected reflections 11,273
Independent reflections 3163 [Rint = 0.0881]
Completeness to 2= 67.20 94.0%
Refinement method Full-matrix least-square on F2
Absorption correction 1.000–0.749
Data/restrains/parameters 3163/0/272
Goodness-of-fit on F2 1.058
Final R indices [I > 2F(I)] R1 = 0.0595, wR2 = 0.1550
R indices (all data) R1 = 0.0722, wR2 = 0.1721
Largest difference peak and hole (e. A˚−3) 0.58 and −0.65
Figure 1. ORTEP-3 view of the asymmetric unit of FMT-MLT showing the atoms labeling, the 50% probability ellipsoids, and classical (blue
dashed lines) and nonclassical (blue light dashed lines) H-bond interactions.
The maleic acid moiety adopts a nearly planar conforma-
tion according to the dihedral angle C(1)–C(2)–C(3)–C(4) of
−2.90(1)◦. In addition, an intramolecular H-bond involving the
O(3) atom and the C(1)–O(1)–O(2)–H carboxylic group, forming
a seven-membered ring, is observed (Table 2).
The crystal structure presents a three-dimensional packing
stabilized by a complex pattern of H-bond intermolecular in-
teractions as can be seen from Figure 2. The corresponding
geometrical parameters are listed in Table 2. Each (FMT)+ in
the FMT-MLT interacts with two coformer molecules through
N(1)–H(1B) . . . (O4), N(1)–H(1A) . . . O(2), N(2)–H(1A) . . . O(1), and
N(3)–H(3N) . . . (O3) H-bonds, giving rise to the formation of
two heterosynthons N–H. . . O (Fig. 2a) exhibiting a R22 8 mo-
tif. These interactions are responsible for the deviation in the
N(1)–C(5)–N(2) bond angle when compared with the expected
values from the statistical analysis performed using MOGUL39
program (Fig. S6). The H-bonds previously described involving
all the N atoms of the guanidinium group lead to the formation
of infinite tapes along the b axis (Fig. 2b). Each methylthio-
propyl side chain of (FMT)+ in FMT-MLT interacts through
H-bonds (see Fig. S7), thus leading to the three-dimensional
packing. The N(5)–H(5B) . . . O(5)H-bond connects the primary
amine of the side chain of (FMT)+ with the O(5) atom of the
sulfamoyl group of another (FMT)+ determining columns along
the c axis that are further linked by the N(5)–H(5A) . . . O(6)
intermolecular H-bond. Finally, B–B stacking interactions be-
tween adjacent tapes are observed in the three-dimensional
packing. However, it is interesting to note that in FMT-MLT,
these interactions are not the conventional ones, that is, be-
tween two ordinary aromatic rings. They can be described as
hybrid B–B stacking interactions because they occur between a
quasiaromatic ring (formed as a result of the RAHB effect) and
DOI 10.1002/jps.24196 Russo et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:3754–3763, 2014
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Table 2. Geometrical Parameters of the Intra- and Intermolecular
Hydrogen Bonds (with e.s.d.’s in Parenthesis) of FMT-MLT
D–H. . . A D–H (A˚) D . . . A (A˚) H . . . A (A˚) D–H. . . A (◦)
Intramolecular H-bonds
N(2)–H(2B) . . . N(4)a 0.860 2.725(6) 2.066 132.9
N(5)–H(5A) . . . O(6)a 0.860 2.707(10) 2.063 131.1
O(2)–H(2M) . . . (O3)a 1.100 2.420(5) 1.392 152.1
C(10)–H(10A) . . . N6a 0.970 2.980(17) 2.795 91.3
Intermolecular H-bonds
N(1)–H(1B) . . . (O4)a 0.860 2.881(6) 2.027 171.7
N(3)–H(3N) . . . (O3)a 0.896 2.749(5) 1.868 167.2
N(2)–H(2A) . . . O(1)b 0.860 2.817(5) 1.963 171.6
N(1)–H(1A) . . . O(2)b 0.860 2.927(5) 2.082 167.0
N(5)–H(5A) . . . O(6)c 0.860 2.958(9) 2.527 112.0
N(5)–H(5B) . . . O(5)d 0.860 2.959(10) 2.122 164.3
Symmetry operations: a)x,y,z; b)x,−y+1/2, +z+1/2; c)−x+1,−y+1,+z+1;
d)x,−y-1/2,z+1/2.
D, donor; A, acceptor.
an ordinary aromatic ring.46 In our case, the hybrid B–B stack-
ing interaction is observed between the previously described
H(2A)–N(2)–C(5)–N(3)–C(6)–N(4) ring and the thiazole ring
(see Fig. 2b). The distances between centroids (Ct) are 3.497
A˚ for Ct1–Ct2 and 3.623 A˚ for Ct1′–Ct2′ that indicates that
adjacent chains are not completely parallel. The displacement
angles are 3.91◦ and 3.38◦ for Ct1–Ct2 and Ct1′–Ct2′, respec-
tively, determining a nearly cofacial orientation between both
rings.
Table 3. Dihedral Angles of the Methylthiopropyl Side Chain in
A-FMT and FMT-MLT (with e.s.d.’s in Parenthesis)
Angle
Denomination Fragment A-Form (◦)a FMT-MLT (◦)
1 N(4)-C(8)-C(9)-S(2) −79.17(3) −65.00(6)
2 C(8)-C(9)-S(2)-C(10) −71.51(3) −68.10(6)
3 C(9)-S(2)-C(10)-C(11) −83.34(2) −79.39(1)
4 S(2)-C(10)-C(11)-C(12) 68.03(3) 175.84(9)
aFrom Overgaard et al.18
FTIR Analysis
The FTIR spectra of FMT-MLT, A-FMT, and B-FMT are dis-
played in Figure 3. Because of their complexity, the analysis
is focused in those FMT functional groups directly involved in
the intermolecular interactions with the maleic acid (see Table
S2). Expected differences were found in the FMT-MLT spec-
trum when it was compared with those of FMT polymorphs.
The broad band centered at 3425 cm−1 that is associated with
the (NH) mode of the guanidinium group is shifted to lower
frequencies in FMT-MLT spectrum while the corresponding
*(NH) mode appears at higher ones. These shifts are consis-
tent with the presence of several H-bonds in the crystal lattice
mainly involving the guanidinium group of (FMT)+ and the
(MLT)−. Moreover, we propose that the broad feature of the
former band is because of the contribution of the L(O–H) be-
longing to the carboxylic group; the lowering in its frequency
value when compared with that of the free carboxylic group
Figure 2. Famotidine-MLT crystal packing. (a) View along the c axis (the intermolecular H-bond interactions in guanidinium group are
displayed in light blue). (b) View along the b axis.
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Figure 3. Fourier transform infrared spectra of (a) A-FMT, (b) B-FMT, and (c) FMT-MLT.
(assigned in the range 3560–3500 cm−1) is associated with the
(O(2)–H(2M) . . .O(3)) intramolecular H-bond between the car-
boxylate and carboxylic groups of the MLT ion (see Fig. 1). Re-
garding the L(C=N) mode, it appears in the region comprised
between 1640 and 1560 cm−1. A band at 1562 cm−1 in the FMT-
MLT spectrum is assigned to the LN(1)–C(5) and LN(2)–C(5)
modes, whereas the LN(3)–C(5) one occurs at 1638 cm−1. The
assignment is in agreement with the structural data that de-
termines similar bond distances for N(1)–C(5) and N(2)–C(5)
and a shorter one for the N(3)–C(5) bond in the guanidinium
group.
The bands originated in the vibrational modes of the
carboxylic and carboxylate groups can also be identified in
the FMT-MLT spectrum. The band centered at 1707 cm−1
is assigned to L[C(1)=O(1)] mode of the former group. The
Las[O(4)–C(4)–O(3)] mode is associated with a broad band
centered at 1562 cm−1—overlapped with the L(C=N) mode—
whereas the corresponding symmetric mode is assigned to the
band located at 1358 cm−1.
Thermal Analysis
Figure 4a displays the DSC profile of FMT-MLT in comparison
with the corresponding ones of A- and B-FMT. The melting pro-
cesses of both polymorphs are consistent with those reported
in the literature,25,32,47,48 the melting points being 171.04 ±
0.98◦C and 161.55 ± 1.23◦C for A-FMT and B-FMT, respec-
tively. A higher thermal stability is evidenced for FMT-MLT as
the melting process occurs at 186.09 ± 0.86◦C, approximately
15◦C higher than the more stable polymorph. Additionally, the
hot-stage microphotographs are in good agreement with the
DSC data (Fig. 4b).
Thermogravimetric analysis indicates that FMT-MLT de-
composes in two well-defined steps (Fig. S8), the first one cor-
responding to a 35.13% weight loss (calculated: 33.29%; on
set: 191.53◦C). In an attempt to elucidate this process, a small
amount of sample was heated at the appropriate temperature
and then the corresponding FTIR spectrum was recorded. The
absence of the IR bands derived from the SO2 modes, the pres-
ence of the L[C(1)=O(1)], belonging to the coformer, as well as
the band at 1502 cm−1, corresponding to L(thiazole),49 confirm
the breakdown of the S(2)–C(10) bond (see Scheme S1). In the
second step, a mass decay of 63.65% (calculated: 64.84%; on set:
516.89◦C) is observed, leading to the complete decomposition of
the compound.
Synthesis of FMT-MLT by the Comilling Process
The solid-state preparation of new molecular complexes with
improved properties by interaction of an API and a suitable
coformer offers several advantages such as a more environ-
mentally friendly synthesis, an experimental design free from
solubility considerations,50 and most importantly it has become
the preferred methodology for industrial-scale processes in the
pharmaceutical industry. Thus, the comilling method was also
probed for the system FMT–maleic acid, and FMT-MLT was
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Figure 4. (a) Differential scanning calorimetry profiles and (b) hot-stage microphotographs of (I) A-FMT, (II) B-FMT, and (III) FMT-MLT.
Figure 5. (a) Bar diagram of RDC (n = 3). (b) PXRD of FMT-MLT obtained by solvent evaporation method versus FMT-MLT obtained at 120
min of milling. (c) SEM microphotographs of FMT-MLT and FMT-MLTCM. (I) and (II) FMT-MLT at 70× and 500×, respectively. (III) and (IV)
FMT-MLTCM at 70× and 300×, respectively. (d) DSC profiles at different milling times. (I) A-FMT, (II) B-FMT, (III) 30 min, (IV) 60 min, (V) 90
min, (VI) 120 min, (VII) 150 min, and (VIII) 180 min of milling.
Table 4. Solubility Values in Water and SGF (mg mL−1)
Medium Dissolution FMT A FMT B FMT- MLT FMT- MLTCM
Water 0.768 ± 0.007 0.984 ± 0.068 1.239 ± 0.049 1.241 ± 0.029
SGF 1.280 ± 0.072 1.667 ± 0.059 2.798 ± 0.330 2.510 ± 0.293
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obtained according to the PXRD patterns at different times of
the milling process shown in Figure S9; the diffractograms of
A-FMT and B-FMT are also included for comparison. As can
be seen, the powder diagrams recorded every 30 min of milling
do not show the diffraction peaks corresponding to the initial
reagents and only the diffraction peaks characteristic of FMT-
MLT are observed. These diffraction peaks remain up to 150
min of milling, whereas a poorly crystalline sample is obtained
at 180 min. As the milling time modifies the crystallinity, the
RDC% was calculated to optimize the time where the most
crystalline FMT-MLT is obtained. Taking into account the re-
sults of the RDC% values at different milling times displayed in
Figure 5a, the crystallinity of the sample at 120 min is similar
to that corresponding to the compound obtained by the solvent
evaporation method (Fig. 5b). So, further analyses described
here were performed on this sample, named FMT-MLTCM from
now on. In order to determine whether crystallinity of FMT-
MLTCM remains over time and also at different temperatures,
the polycrystalline powder was placed under dry conditions in
a desiccator at 4◦C, 25◦C, and 40◦C for 60 days. It was verified
that the crystallinity is retained during that period at all tested
temperatures (Fig. S10). This high stability is attributed to a
solid-state reaction (acid-base reaction) between both reagents
during the milling process.51
The SEM microphotographs of FMT-MLT in comparison
with those of FMT-MLTCM are shown in Figure 5c. The
cogrinding process produces a larger particle size than that
obtained by the solvent evaporation method. Besides, FMT-
MLT crystallizes as planar bars, whereas FMT-MLTCM ex-
hibits a nonregular block shape that is more appropriate for
develop formulations. Additionally, the vibrational and ther-
mal behaviors of FMT-MLTCM and FMT-MLT are identical.
Figure S11 shows the FTIR spectra and DSC curves of both
compounds.
To investigate the eventual formation of an amorphous com-
pound during the comilling process, DSC analysis was per-
formed in order to find thermal properties inherent to poorly
crystalline compounds (i.e., Tg and Tc). The DSC diagrams up
to 200◦C at different milling times are displayed in Figure 5d.
The DSC curves of A- and B-FMT were also included for com-
parison. According to the DSC analysis, the thermal behavior of
the comilled samples at different intervals studied is consistent
with that observed for FMT-MLT (see section Thermal Analy-
sis). Moreover, no traces of the reagents were detected, that is,
melting, this fact being indicative of complete reaction between
FMT andmaleic acid. Additional signals to those corresponding
to themelting and decomposition processes are only observed in
the sample obtained at 180 min of milling (Fig. 5d, VIII). Firs,
a weak endothermic signal at 59.35 ± 1.32◦C is attributable
to the Tg, whereas the exothermic event at 113.38 ± 0.87◦C
could be associated to TC. These data are in agreement with
the PXRD results that demonstrate the lowest crystallinity for
the sample milled during 180 min.
Solubility Assays
The solubility values determined in water for FMT-MLT and
FMT-MLTCM along with those for both FMT polymorphs are
gathered in Table 4. The water solubility values of A-FMT
and B-FMT are in agreement with those previously reported.52
FMT-MLT presents higher solubility than the polymorphs of
the parental drug as increments of 1.68 and 1.25 times are ob-
served when compared with the A- and B-FMT, respectively.
No significant differences in the solubility values were found
between FMT-MLT and FMT-MLTCM.
As FMT is absorbed in the stomach cavity, the solubility as-
says in water do not represent the gastrointestinal conditions.
To clarify that, the solubility was also measured in SGF. How-
ever, under these conditions (pH 2, 37◦C), FMT is highly un-
stable. Taking into account the degradation kinetics proposed
by Wu and Fassihi,53 we determine the solubility at 60 min be-
cause of the degradation products are kept to minimum (less
than 5%) in that period. The corresponding data are collected
in Table 4. An increase in the solubility values in SGF versus
water is evident in all cases. FMT-MLT shows increments of
1.67 and 1.23 times compared with A- and B-FMT, respectively,
whereas FMT-MLTCM exhibits a similar performance.
CONCLUSIONS
Crystalline engineering concepts were employed to overcome
the polymorphism issue of FMT by obtaining a new FMT
salt with improved solubility and thermal stability with re-
spect to FMT polymorphs that enable its use in commercial
formulations. Single crystals of the salt were obtained by
the solvent evaporation method (FMT-MLT) and microcrys-
talline powder was synthesized by the comilling procedure
(FMT-MLTCM). Both synthesis methods were performed from
a commercial mixture of A- and B-FMT leading to a unique
compound, without requiring the previous polymorphic sepa-
ration that might produce an increase in the production costs.
Single-crystal X-ray diffraction determines that FMT moiety
in FMT-MLT adopts an extended conformation that is stabi-
lized by intramolecular H-bonds. The three-dimensional pack-
ing shows a complex pattern of H-bonds. These interactions
generate infinite tapes along the b axis and columns along the
c one. Adjacent tapes show nonconventional B–B stacking inter-
actions between the thiazole and the quasiaromatic rings. The
vibrational behavior is consistent with the structural findings.
Thermal studies indicate that the salt melts at a higher tem-
perature than the A-FMT and the pharmacologically preferred
polymorph B. Finally, solubility experiments in water and SGF
demonstrated that FMT-MLT exhibits a better performance
than FMT polymorphs A and B.
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